Form 4: Harrow Inc. CEO John P. Saharek Exercises Stock Options

John P. Saharek, CEO of ImprimisRx (a subsidiary of Harrow, Inc.), exercised stock options to acquire 5,000 shares of common stock at $8.75 per share on March 1, 2024.

Summary

• On March 1, 2024, John P. Saharek, CEO of ImprimisRx, exercised stock options to purchase 5,000 shares of Harrow, Inc. (HROW) common stock.
• The exercise price was $8.75 per share.
• This transaction was executed under the company's 2007 Stock Incentive and Awards Plan.
• Following the transaction, Saharek directly owns 254,803 shares of Harrow, Inc. common stock.
• The stock options were granted on March 3, 2014, and became exercisable over a three-year period.
• The options expired on March 3, 2024.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a standard transaction related to executive compensation and doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This Form 4 filing is a routine disclosure related to executive compensation and stock ownership. It provides transparency into the transactions of company insiders and their alignment with shareholder interests.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• It provides transparency to shareholders regarding executive compensation.

Key Dates